The following articles have showcased Absynth Biologics (please note that we are not responsible for the content of external websites).

  1. Absynth receives £100,000 funding from Yorkshire Forward.  December 2008.  For more information see Absynth News.
  1. BBSRC Leaflet. Jan 2008. Issue: Tackling ‘Superbugs’. New companies take up the fight. Absynth Biologics. p. 14. “… a unique group of surface-exposed proteins of S. aureus … are good novel targets for a vaccine and for prophylactic or therapeutic antibodies control of infection … The research findings are being taken towards clinical application by ABsynth Biologics.” 

Get a copy at: BBSRC Leaflet  General enquiries or comments about the material included in this leaflet contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

  1. BBSRC business. Jul 2007. Spin out sets to tackle MRSA. p. 12. “Through underpinning BBSRC-funded research we have identified a unique pool of immunological targets, with esential roles in cellular physiology and pathogenicity … Absynth Biologics gives an exciting opportunity to translate our basic research into real clinical application”

Get a copy at: BBSRC Business  

  1. Helix - Bioscience cluster news from Yorkshire Forward. May 2007. Issue 07. ABsynth Biologics: Spin out company battles superbug. p. 2. “The concept (Absynth Biologics) uses an immunological approach to target a novel set of proteins ... important for the growth and/or pathogenesis of the bacterium …” 

Enquiries to Dr Danielle Hankin – Yorkshire Forward Bioscience Cluster manager. This email address is being protected from spambots. You need JavaScript enabled to view it.. www.bioscience-yorkshire.com

  1. BBSRC Follow-On Funding. Jan 2007. Case study: Spin out set to tackle MRSA (“Absynth”). BBSRC Follow on Funding Case Study
Paid for by direct debit